Artemis Investment Management LLP lessened its position in shares of Mylan NV (NASDAQ:MYL) by 23.5% in the third quarter, HoldingsChannel.com reports. The firm owned 130,000 shares of the company’s stock after selling 40,000 shares during the quarter. Artemis Investment Management LLP’s holdings in Mylan were worth $4,759,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. Crossmark Global Holdings Inc. increased its position in Mylan by 9.2% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 31,850 shares of the company’s stock valued at $1,166,000 after purchasing an additional 2,690 shares during the period. Alliancebernstein L.P. increased its position in Mylan by 13.8% during the 3rd quarter. Alliancebernstein L.P. now owns 1,206,644 shares of the company’s stock valued at $44,163,000 after purchasing an additional 146,333 shares during the period. Factorial Partners LLC acquired a new stake in Mylan during the 3rd quarter valued at approximately $732,000. Evanston Investments Inc. dba Evanston Advisors increased its position in Mylan by 4.2% during the 3rd quarter. Evanston Investments Inc. dba Evanston Advisors now owns 215,662 shares of the company’s stock valued at $7,893,000 after purchasing an additional 8,640 shares during the period. Finally, Washington Capital Management Inc. increased its position in Mylan by 4.8% during the 3rd quarter. Washington Capital Management Inc. now owns 45,225 shares of the company’s stock valued at $1,655,000 after purchasing an additional 2,075 shares during the period. 81.91% of the stock is owned by institutional investors and hedge funds.
Shares of MYL opened at $33.49 on Friday. Mylan NV has a 12-month low of $30.33 and a 12-month high of $47.82. The company has a current ratio of 1.26, a quick ratio of 0.77 and a debt-to-equity ratio of 1.20. The firm has a market capitalization of $17.21 billion, a P/E ratio of 7.34, a PEG ratio of 1.10 and a beta of 1.53.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, November 5th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.06. Mylan had a return on equity of 19.39% and a net margin of 4.71%. The company had revenue of $2.86 billion for the quarter, compared to analysts’ expectations of $2.91 billion. During the same period last year, the business earned $1.10 EPS. Mylan’s quarterly revenue was down 4.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Mylan NV will post 4.66 earnings per share for the current fiscal year.
A number of equities analysts have issued reports on the company. Leerink Swann cut their price target on Mylan from $53.00 to $47.00 and set an “outperform” rating on the stock in a report on Thursday, August 9th. Raymond James cut Mylan from a “strong-buy” rating to an “outperform” rating in a report on Thursday, August 9th. Cowen restated a “hold” rating and set a $31.00 price target on shares of Mylan in a report on Thursday, August 9th. Cantor Fitzgerald restated a “hold” rating and set a $41.00 price target on shares of Mylan in a report on Wednesday, August 8th. Finally, Wells Fargo & Co set a $41.00 price target on Mylan and gave the stock a “hold” rating in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $46.56.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/24/mylan-nv-myl-holdings-trimmed-by-artemis-investment-management-llp.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Further Reading: What is the quiet period?
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.